



## Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy



Julia Ruark<sup>1</sup>, Erin Mullane<sup>2</sup>, Nancy Cleary<sup>2</sup>, Ana Cordeiro<sup>2,3</sup>, Evandro D. Bezerra<sup>4</sup>, Vicky Wu<sup>5</sup>, Jenna Voutsinas<sup>5</sup>, Bronwen E. Shaw<sup>6</sup>, Kathryn E. Flynn<sup>6</sup>, Stephanie J. Lee<sup>2,4</sup>, Cameron J. Turtle<sup>2,4,7</sup>, David G. Maloney<sup>2,4,7</sup>, Jesse R. Fann<sup>1</sup>, Merav Bar<sup>2,4,\*</sup>

<sup>1</sup> Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington

<sup>2</sup> Clinical Research division, Fred Hutchinson Cancer Research Center, Seattle, Washington

<sup>3</sup> Public Health division, Fred Hutchinson Cancer Research Center, Seattle, Washington

<sup>4</sup> Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, Washington

<sup>5</sup> Department of Medicine, University of Washington, Seattle, Washington

<sup>6</sup> Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin

<sup>7</sup> Centro Paulista de Oncologia, Sao Paulo, Brazil

### Article history:

Received 1 August 2019

Accepted 29 September 2019

### Key Words:

CD19-targeted CAR T cells

Late events

Patient-reported outcomes

### A B S T R A C T

CD19-targeted chimeric antigen receptor (CAR) modified T cell immunotherapy is a novel treatment with promising results in patients with relapsed/refractory lymphoid malignancies. CAR T cell therapy has known early toxicities of cytokine release syndrome and neurotoxicity, but little is known about long-term neuropsychiatric adverse effects. We have used patient-reported outcomes, including Patient-Reported Outcomes Measurement Information System (PROMIS) measures, to assess neuropsychiatric and other patient-reported outcomes of 40 patients with relapse/refractory chronic lymphocytic leukemia, non-Hodgkin lymphoma, and acute lymphoblastic leukemia 1 to 5 years after treatment with CD19-targeted CAR T cells. Mean T scores of PROMIS domains of global mental health, global physical health, social function, anxiety, depression, fatigue, pain, and sleep disturbance were not clinically meaningfully different from the mean in the general US population. However, 19 patients (47.5%) reported at least 1 cognitive difficulty and/or clinically meaningful depression and/or anxiety, and 7 patients (17.5%) scored  $\leq 40$  in global mental health, indicating at least 1 standard deviation worse than the general population mean. Younger age was associated with worse long-term global mental health ( $P = .02$ ), anxiety ( $P = .001$ ), and depression ( $P = .01$ ). Anxiety before CAR T cell therapy was associated with increased likelihood of anxiety after CAR T cell therapy ( $P = .001$ ). Fifteen patients (37.5%) reported cognitive difficulties after CAR T cell therapy. Depression before CAR T cell therapy was statistically significantly associated with higher likelihood of self-reported post-CAR T cognitive difficulties ( $P = .02$ ), and there was a trend for an association between acute neurotoxicity and self-reported post-CAR T cognitive difficulties ( $P = .08$ ). Having more post-CAR T cognitive difficulties was associated with worse global mental health and global physical health. Our study demonstrates overall good neuropsychiatric outcomes in 40 long-term survivors after CAR T cell therapy. However, nearly 50% of patients in the cohort reported at least 1 clinically meaningful negative neuropsychiatric outcome (anxiety, depression, or cognitive difficulty), indicating that a significant number of patients would likely benefit from mental health services following CAR T cell therapy. Younger age, pre-CAR T anxiety or depression, and acute neurotoxicity may be risk factors for long-term neuropsychiatric problems in this patient population. Larger studies are needed to confirm these findings.

© 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.

### INTRODUCTION

CD19-targeted chimeric antigen receptor modified T-cell immunotherapy (CD19 CAR T cells) has shown excellent anti-tumor activity in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) [1] and non-Hodgkin lymphoma

(NHL) [2,3], which led to the approval of tisagenlecleucel (Kymriah, Novartis; New Jersey, USA) and axicabtagene ciloleucel (Yescarta, (Kite (A Gilead Company); Santa Monica, CA, USA) by regulatory agencies in the United States, Europe, Canada, Japan, and Australia. This approval has transformed the care of patients with relapsed/refractory ALL and aggressive B cell NHL [4–6].

At the Fred Hutchinson Cancer Research Center (FHCRC), a phase I/II clinical trial using CD19 CAR T cells demonstrated

*Financial disclosure:* See Acknowledgments on page 42.

\*Correspondence and reprint requests: Merav Bar, MD, Fred Hutchinson Cancer Research Center, PO Box 19024, Seattle, WA 98109-1024.

E-mail address: [mbar@fredhutch.org](mailto:mbar@fredhutch.org) (M. Bar).

high response rates in patients with relapsed/refractory ALL (85% of patients achieved minimal residual disease (MRD)-negative complete remission), NHL (51% overall response rate (ORR); 40% complete response (CR)), and chronic lymphocytic leukemia (CLL) (74% ORR; 21% CR) [7–9].

CD19 CAR T cells cause unique early toxicities, such as cytokine release syndrome (CRS) [10–14] and acute neurotoxicity [15,16]. CRS is a systemic inflammatory response that arises within several days of the CAR T infusion and may manifest as fever, hypotension, capillary leak syndrome, and multiorgan failure. Severe CRS may affect 10% to 40% of patients [17]. Acute neurotoxicity can manifest as a multitude of different neurologic adverse events, including but not limited to confusion, expressive aphasia, obtundation, myoclonus, and seizure. Severe neurotoxicity may affect 10% to 40% of patients [17]. CAR T cell product, CAR T cell dose, and patients' characteristics (such as disease treated, disease burden, or prior neurologic conditions) may affect rates and manifestations of CRS and neurotoxicity. CRS and neurotoxicity can be fatal, but with appropriate monitoring and treatment, they typically resolve within days to a couple of weeks after CAR T cell infusion [17]. However, potential long-term neuropsychiatric adverse effects of CAR T cells as well as CRS and acute neurotoxicity are still not fully elucidated [18].

Until recently, the only cellular therapy modality for the treatment of hematologic malignancies had been allogeneic hematopoietic cell transplantation (HCT), which provides immune response against tumor cells derived by alloreactive donor cells but with the risk of acute and chronic graft-versus-host disease (GVHD) as well as other late effects that adversely affect morbidity, mortality, and quality of life of transplant survivors, including significant neuropsychiatric effects [19]. At this time, only limited data are available regarding the long-term effects of CAR T cell therapy [18]. Thus, it is important to evaluate the late neuropsychiatric effects of CAR T and evaluate their effect on survivors' quality of life.

Patient-reported outcomes (PROs), a method of measuring health status directly from the patient without clinician interpretation, have been demonstrated to be a reliable tool for evaluation of treatment-related toxicities [20–22]. A number of studies have used PROs to evaluate symptoms in patients with cancer [23–25] and functional deficits and late effects after HCT [26,27]. In addition, PROs have been used to evaluate outcomes and quality of life after treatment with immune checkpoint inhibitors [28,29]. These studies reveal that patient-reported global health status and quality of life were better among patients treated with immune checkpoint inhibitors compared to patients treated with standard chemotherapy [29–33]. Recently there has been interest in incorporating PROs for evaluation of patients after CAR T cell therapy [34]. Standardized PRO measurement systems, such as the Patient-Reported Outcomes Measurement Information System (PROMIS), allow comparisons across patients with different diseases and treatment histories. PROMIS uses modern psychometric theory to standardize PRO assessment for use in both clinical research and health care delivery settings, including oncology settings [24,35–37]. A key feature of PROMIS is that scores are not disease or treatment specific and thus are applicable for use in settings where multiple different diseases and treatment histories may be represented in the patient population. Thus, we have incorporated PROs, including PROMIS measures for evaluation of symptoms and function of long-term survivors after CAR T cell therapy.

The aim of this study was to use PROs to evaluate the frequency and potential risk factors for adverse neuropsychiatric and other patient-reported outcomes in long-term survivors of CAR T cell therapy.

## PATIENTS AND METHODS

### Study Population

The study cohort included 40 patients with relapsed/refractory ALL, NHL, or CLL treated with CD19-targeted CAR T cells on a phase I/II clinical trial (NCT01865617) between December 2013 and February 2018 and survived at least 12 months after treatment (in remission or with disease progression). The study was approved by the FHCRC Institutional Review Board, and all patients provided informed consent for treatment and for long-term follow-up.

### Clinical Data

Clinical and sociodemographic variables were abstracted from each patient's chart. These included age, sex, race, employment status, marital status, medical and psychiatric history, date of CAR T cell infusion, CRS grading based on the Lee et al. [10] criteria, and acute neurotoxicity grading based on the National Cancer Institute Common Toxicity Criteria for Adverse Events version 4.03.

All patients underwent evaluation before CAR T cell therapy, including social and psychiatric history. Most patients also underwent standardized mental health screening by a clinical social worker using validated instruments (e.g., the 2- or 9-item Patient Health Questionnaire [PHQ-2/9], the 2- or 7-item Generalized Anxiety Disorder scale [GAD-2/7]) [38–41]. Several patients underwent additional evaluations by a consulting psychiatrist or psychologist.

Pre-CAR T (current or history of) depression was defined as having any of the following: (1) PHQ-2  $\geq 3$ , (2) PHQ-9  $\geq 10$ , (3) a charted diagnosis of a depressive disorder (major depressive disorder, mixed depression and anxiety, adjustment disorder with depression), or (4) prescribed antidepressant medication before CAR T cell therapy. Pre-CAR T anxiety was defined by having any of the following: (1) GAD-2  $\geq 3$ , (2) GAD-7  $\geq 10$ , (3) charted diagnosis of an anxiety disorder, or (4) prescribed anxiolytic medications that were clearly listed for treatment of anxiety. All patients on an antidepressant had a charted diagnosis of anxiety, depression, or both and so were categorized under the appropriate diagnosis. Baseline sleep disturbance was determined by either a charted diagnosis of insomnia or a charted prescription for a medication that was being used to treat sleep disturbance.

### Assessments and Measures

A link to an online questionnaire was emailed to patients who were at least 1 year after CAR T cell therapy and at  $\pm 2$  months of their yearly anniversary of T cell infusion between October 2018 through February 2019; if requested by the patient, a paper form questionnaire was sent.

The questionnaire included the PROMIS Scale v1.2 Global Health and the PROMIS-29 Profile v2.1, as well as 30 additional questions, including 4 questions pertaining to cognitive function. PROMIS-Global Health is an overall evaluation of physical and mental health consisting of 10 items and scored as a global physical health component and a global mental health component. PROMIS-29 contains 7 domains, each 4-item short forms, assessing depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and ability to participate in social roles and activities, plus 1 item assessing pain intensity. Symptom domains (depression, anxiety, fatigue, sleep disturbance, pain) were assessed in the past 7 days. There were no time restrictions for function domains. Additional questions included demographic data, cancer disease status, additional diagnoses and symptoms that patients may have developed since CAR T cell therapy, current medications, and evaluation of cognitive functioning. Cognitive functioning was assessed by questions we developed that asked if patients had experienced difficulties with concentration, finding words, memory, or solving problems since their CAR T cell therapy; an answer of "yes" to each of those 4 questions received 1 point to determine the total cognitive difficulty score (0 to 4).

The PROMIS measures were scored using the HealthMeasures Scoring Service ([https://www.assessmentcenter.net/ac\\_scoringservice](https://www.assessmentcenter.net/ac_scoringservice)). Raw scores were converted to standardized T scores that can be compared with normative data from the US general population. T-score distributions are standardized such that a score of 50 points represents the mean for the US general population, and the standard deviation around that mean is 10 points. A higher PROMIS T score indicates more of the concept being measured. For symptom measures such as anxiety, depression, sleep disturbance, pain, and fatigue, a higher score indicates worse symptoms (e.g., a T score of 60 indicates 1 standard deviation increased anxiety compared with the mean for the US general population, and a score of 40 indicates 1 standard deviation less anxiety than the general population). For functional domains, including global mental and physical health, social function, and physical function, a higher score indicates better function (e.g., a T score of 60 indicates 1 standard deviation better mental health function than the average for the general US population, and a T score of 40 indicates 1 standard deviation worse mental health function compared with the average for the general US population) (PROMIS, 2015: [https://www.assessmentcenter.net/documents/PROMIS\\_Profile\\_Scoring\\_Manual.pdf](https://www.assessmentcenter.net/documents/PROMIS_Profile_Scoring_Manual.pdf)). Clinically meaningful difference was defined as half of a standard deviation (a 5-point difference in T score) [23,26,42].

### Statistical Methods

Baseline demographics, clinical characteristics, and PROMIS measures were summarized by medians or means with standard deviation and range for continuous variables and numbers and proportions for categorical variables. The strength of association between PROMIS scores was evaluated by Spearman correlation coefficients ( $r$ ). To show the trends in PROMIS scores by the number of cognitive difficulties, we used box plots and calculated  $P$  values using linear regression, treating cognitive difficulties as a continuous measure. Histograms were generated for each of the PROMIS T scores to show the sample distribution, and 2-sided  $P$  values were calculated by a 1-sample  $t$  test to compare our sample to the US general population's T score mean of 50. Univariate analyses were conducted on the neuropsychiatric outcomes of particular interest. Linear regression was used to analyze continuous scores (PROMIS global mental health, PROMIS global physical health, PROMIS anxiety, PROMIS depression), and logistic regression was used to analyze cognitive difficulties (any versus none). Depression or anxiety that was diagnosed before CAR T cell therapy (pre-CAR T depression or pre-CAR T anxiety) was included in the models to adjust for a baseline effect if appropriate. Multivariate analyses were performed on selected outcomes using stepwise selection, with a  $P$  value threshold of less than .10 for model entry and exit. All variables in the univariate analyses were included in the multivariable selection process, and the threshold of .10 guaranteed inclusion of all variables with a  $P$  value  $<$ .10 in the model [7,43]. Due to the limited sample size and the nature of exploratory analysis, multiplicity adjustments were not considered. All analyses were conducted using R, version 3.4.1.

## RESULTS

### Questionnaire Response Rate

Between October 2018 and February 2019, 38 patients were emailed a link to the electronic questionnaire and 14 patients were provided a hard copy of the questionnaire (per their request or due to inability to contact patients via email). As of February 28, 2019, 40 questionnaires had been returned and included in the analysis (29 of 38 electronic questionnaires and 11 of 14 hard-copy questionnaires, for a total response rate of 76.9%).

### Patient Characteristics

The median (SD) age of the patients in the study cohort was 54 (11.9) years (range, 22 to 74) at the time of CAR T cell therapy and 57 (11.7) years (range, 26 to 76) at the time of questionnaire completion. The majority was male (62.5%), white (82.5%), and married (77.5%). Patients received CAR T cell therapy for NHL (35%), CLL (37.5%), and ALL (27.5%). Median lines of treatment before CAR T were 5 (range, 1 to 10). Six patients (15%) had a history of central nervous system involvement at any time during the disease course before CAR T cell therapy, and 14 patients (35%) received directed central nervous system chemotherapy as treatment or prophylaxis. The majority of patients had maximum CRS grade 1 (30%) or 2 (40%), and the majority of patients did not have acute neurotoxicity (62.5%). Four patients (10%) had maximum grade 3 CRS and 4 patients (10%) had maximum grade 3 neurotoxicity. Two patients (5%) had maximum grade 4 CRS and 2 patients (5%) had maximum grade 4 neurotoxicity (1 of those patients had both grade 4 CRS and grade 4 neurotoxicity). The median time from CAR T cell therapy to questionnaire completion was 3 years (range, 1 to 5). Twenty-three patients (57.5%) received additional treatment(s) after CAR T cell therapy (including 12 allogeneic hematopoietic cell transplantations [HCTs], given as consolidation or salvage), and 33 patients (82.5%) were in remission at the time of questionnaire completion. Characteristics of the cohort are shown in Table 1.

### Psychiatric History before CAR T Cell Therapy

Twelve (30%) patients met our criteria for pre-CAR T depression, 17 (42.5%) met our criteria for pre-CAR T anxiety, and 18 (45%) met criteria for pre-CAR T sleep disturbance. Immediately before CAR T therapy, 8 (20%) of the patients

**Table 1**

Demographic and Clinical Characteristics (N = 40)

Variable	Value
<b>Demographic</b>	
Age at time of CAR T cell therapy, yr	
Median (SD)	54 (11.9)
Range	22.0-74.0
Age at questionnaire completion	
Median (SD)	57 (11.7)
Range	26.0-76.0
Years after CAR T cell therapy, median (range)	3 (1-5)
<b>Sex</b>	
Male	25 (62.5)
Female	15 (37.5)
<b>Race</b>	
American Indian/Alaska Native	1 (2.5)
Asian	3 (7.5)
Asian, white	1 (2.5)
White	33 (82.5)
Unknown	2 (5.0)
<b>Marital status</b>	
Married	31 (77.5)
Single/divorced/widowed	9 (22.5)
<b>Employment status at time of questionnaire completion</b>	
Working	17 (42.6)
Unable to work due to health	11 (27.5)
Not working but not due to health	12 (30.0)
<b>Medical</b>	
<b>Diagnosis</b>	
ALL	11 (27.5)
CLL	15 (37.5)
NHL	14 (35.0)
<b>Number of prior lines of therapy</b>	
Median (SD)	5 (1.9)
Range	1-10
<b>Prior HCT before CAR T</b>	
Autologous (auto)	4 (10.0)
Allogeneic (allo)	11 (27.5)
Auto and allo	2 (5.0)
No HCT	19 (47.5)
<b>Prior radiation before CAR T</b>	
Local radiation (no cranial)	7 (17.5)
Total body irradiation (low dose; $\leq$ 4 Gy)	7 (17.5)
Total body irradiation (high dose; $\geq$ 12 Gy)	3 (7.5)
<b>CNS disease involvement at any time before CAR T cell therapy</b>	
No	34 (85.0)
Yes	6 (15.0)
<b>CNS-directed chemotherapy (as treatment for CNS involvement or prophylaxis)</b>	
No	26 (65.0)
Yes	14 (35.0)
<b>Maximum cytokine release syndrome grade</b>	
0	6 (15.0)
1	12 (30.0)
2	16 (40.0)
3	4 (10.0)
4	2 (5.0)

(continued)

**Table 1** (Continued)

Variable	Value
Maximum neurotoxicity grade	
0	25 (62.5)
1	1 (2.5)
2	8 (20.0)
3	4 (10.0)
4	2 (5.0)
Additional treatment after CAR T cell therapy*	
No	17 (42.5)
Yes	
Allo HCT	12 (30.0)
Targeted therapy	12 (30.0)
Local radiation (no cranial)	2 (5.0)
CAR T cell therapy	2 (5.0)
Checkpoint inhibitors	1 (2.5)
Remission status at time of questionnaire completion	
In remission	33 (82.5)
Not in remission	7 (17.5)
Pre-CAR T psychiatric problems	
Depression	
No	28 (70.0)
Yes	12 (30.0)
Anxiety	
No	23 (57.5)
Yes	17 (42.5)
Sleep disturbance	
No	22 (55.0)
Yes	18 (45.0)

Values are presented as number (%) unless otherwise indicated. NHL includes diffuse large B cell lymphoma (n = 7), high-grade B cell lymphoma (n = 1), Burkitt lymphoma (n = 1), mantle cell lymphoma (n = 3), and follicular lymphoma (n = 2). CNS indicates central nervous system.

\* Some patients received more than 1 treatment.

were on antidepressant medications, 12 (30%) were on anxiolytic medications, and 18 (45%) were prescribed medications for sleep disturbance.

**Psychiatric and Cognitive Outcomes after CAR T Cell Therapy**


As demonstrated in Figure 1, at the time of questionnaire completion, 8 (20%) patients reported clinically meaningful depression or anxiety (PROMIS T score >55) and at least 1 cognitive difficulty, 4 (10%) reported depression or anxiety but no cognitive difficulties, and 7 (17.5%) reported cognitive difficulties with no depression or anxiety. Twenty-one (52.5%) patients reported no neuropsychiatric symptoms.

At the time of questionnaire completion, 10 (25%) patients reported being on medications for depression, 8 (20%) reported being on anxiolytics, and 6 (15%) reported being on medications for sleep (Table 2). The use of medications for depression and sleep (as per patients’ report) was statistically significantly lower at the time of questionnaire completion compared with immediately before CAR T cell therapy (P = .03, P = .007 respectively), whereas the use of anxiolytic medications was not statistically significantly different (P = .44).

Fifteen (37.5%) patients reported 1 or more cognitive difficulties. Fourteen (35%) of the patients reported having difficulty with memory, 12 (30%) reported difficulty finding words, 9 (22.5%) reported difficulty with concentration, and 5 (12.5%) reported difficulty solving problems. Four (10%) patients reported experiencing all 4 cognitive symptoms.

**PROMIS Outcomes**

PROMIS outcome data (Table 2; Supplementary Figure S1) demonstrate that mean global mental health, global physical health, social function, anxiety, fatigue, pain, and sleep disturbance of the study cohort did not clinically meaningfully differ from that of the general population. However, 5 patients (12.5%) scored ≥60 in anxiety and/or depression and 7 patients (17.5%) scored ≤40 in global mental health, indicating at least 1 standard deviation worse than the general population mean.



**Figure 1.** Distribution of depression, anxiety, and neurocognitive difficulties at time of questionnaire completion. Calculation based on PROMIS T score ≥55.



**Table 2**  
Self-Reported Outcomes 1 to 5 Years after CAR T Cell Therapy

Patient-Reported Outcomes	Value
Neurocognitive difficulties since CAR T cell therapy	
Difficulty concentrating	9 (22.5)
Difficulty with word finding	12 (30.0)
Difficulty with memory	14 (35.0)
Difficulty solving problems	5 (12.5)
Number of cognitive complaints	
0	25 (62.5)
1	1 (2.5)
2	7 (17.5)
3	3 (7.5)
4	4 (10.0)
Taking medications for	
Depression	1 (2.5)
Anxiety	8 (20.0)
Sleep disturbance	6 (15.0)
Fatigue	1 (2.5)
PROMIS measures (T scores), mean (SD)	
Global mental health	48.9 (9.9)
Global physical health	48.8 (10.4)
Ability to participate in social roles and activities	50.9 (10.4)
Anxiety	48.9 (9.0)
Depression	46.3 (8.0)
Sleep disturbance	49.5 (8.3)
Fatigue	48.4 (10.1)
Pain	48.8 (9.3)
Physical function	48.0 (9.6)

Values are presented as number (%) unless otherwise indicated.

### Risk Factors for Neuropsychiatric Outcomes

Univariate analyses of potential risk factors for neuropsychiatric outcomes after CAR T cell therapy are shown in Tables 3 and 4, as well as Supplementary Tables S1 and S2. Younger age was found to be associated with worse PROMIS global mental score ( $P = .02$ ) and worse PROMIS anxiety ( $P = .001$ ) and depression scores ( $P = .01$ ). Anxiety pre-CAR T was associated with PROMIS anxiety post-CAR T ( $P = .001$ ), but depression pre-CAR T was not associated with PROMIS depression post-CAR T ( $P = .60$ ). There was a statistically significant association between pre-CAR T depression and cognitive difficulties (any versus none) (odds ratio = 6.00,  $P = .02$ ), and a suggestive association between neurotoxicity grades 2 to 4 and cognitive difficulties (odds ratio = 3.62,  $P = .07$ ). Longer time since CAR T cell therapy was associated with worse global mental score ( $P = .04$ ). Inability to work due to health issues was associated with worse PROMIS global physical health score ( $P = .001$ ) (Supplementary Table S3), whereas unemployment not due to health issues was associated with better PROMIS anxiety score ( $P = .04$ ) (Supplementary Table S1). Race (white versus others) was not found to be significantly associated with PROMIS global mental score (Table 3), PROMIS anxiety score (Supplementary Table S1), or PROMIS depression score (Supplementary Table S2). However, race might have been associated with reported cognitive status, as 15 of 33 white patients (45%) reported at least 1 cognitive difficulty, whereas none of the 7 nonwhite patients reported cognitive difficulties ( $P = .03$ ) (Table 4). There was no association between disease status at the time of questionnaire completion and patient-reported neuropsychiatric outcomes, and there was no association between allogeneic HCT before or after CAR T cell therapy and reported neuropsychiatric outcomes (Tables 3 and 4).

Multivariate analysis suggested an association between age ( $P = .03$ ) and time of assessment after treatment ( $P = .08$ ) with PROMIS global mental health score (Table 3), as well as an association between pre-CAR T depression ( $P = .02$ ) and acute neurotoxicity (grades 2 to 4 versus 0 to 1;  $P = .08$ ) with cognitive difficulties after treatment (any versus none) (Table 4).

As shown in Figure 2, having more cognitive difficulties was associated with having worse global mental health ( $P = .0001$ ) and global physical health ( $P = .01$ ). Similarly, worse scores for pain interference, sleep disturbance, fatigue, depression, anxiety, physical function, and social function were associated with more cognitive difficulties ( $P = .007$ ,  $P = .0003$ ,  $P = .00006$ ,  $P = .01$ ,  $P = .0007$ ,  $P = .003$ ,  $P = .0004$ , respectively).

Correlation analysis of PROMIS outcomes (Figure 3) shows strong positive correlations ( $r \geq 0.6$ ) between physical and social function, global mental and social function, global physical function and physical function, anxiety and depression, sleep disturbance and fatigue, and fatigue and pain. There was a very strong inverse correlation ( $r \leq -0.8$ ) between fatigue and social function, as well as strong inverse correlations ( $r \leq -0.6$ ) between fatigue and physical function, pain and global physical function, pain and social function, anxiety and global mental function, fatigue and global mental function, and sleep disturbance and global mental function.

### DISCUSSION

CD19-targeted CAR T cell therapy has revolutionized the treatment of relapsed/refractory B cell malignancies, with an unprecedented response rate in this heavily pretreated population. However, data regarding long-term effects after this novel therapy are still scarce. In this study, we examine self-reported long-term neuropsychiatric status and other patient-reported outcomes of patients after CAR T cell therapy.

Patients in our study received a median of 5 lines of therapy before CAR T cells, including HCT in 11 patients (27.5%), and 12 patients (30%) received allogeneic HCT after their CAR T cell therapy. The high rate of prior or subsequent treatment and lack of baseline PRO data before CAR T cell therapy prevents us from determining the direct impact of CAR T cell therapy on outcomes. However, overall, our data demonstrate that the mean self-reported neuropsychiatric status of long-term survivors after CD-19 CAR T cell therapy was not clinically meaningfully different from the general US population.

Cella et al. [25] suggested PROMIS T score thresholds to differentiate severity levels for pain, fatigue, anxiety, and depression in patients with cancer, and our outcomes fell within the designated “normal” range for patients with cancer. Jensen et al. [24] proposed reference mean T scores for PROMIS measures in patients with cancer 6 to 13 months after initial diagnosis, and our study cohort’s mean T scores are equivalent to or slightly better than those values—for example, fatigue (48.4 versus 52.2), pain (48.8 versus 52.4), and physical function (48.8 versus 44.8). The authors included a subset of patients with NHL, and compared with that group, our study cohort demonstrated slightly better mean T scores in depression (46.3 versus 49.3), fatigue (48.4 versus 52.2), and pain (48.8 versus 51.9), but the differences are below the 5-point threshold we consider a clinically meaningful difference. Despite these overall mean scores, nearly 1 in 5 patients in our cohort scored at least 1 standard deviation lower than the general and cancer populations’ means in global mental health, indicating that a significant number of patients would likely benefit from additional mental health services in the years following CAR T therapy.

**Table 3**  
Risk Factor Regression Analyses for PROMIS Global Mental Health T Score

Variable	Coefficient	Standard Error	P Value
Univariate analysis*			
Demographics			
Age at time of CAR T therapy	0.30	0.12	.02
Sex (male versus female)	−0.01	3.57	1.00
Race (white versus other)	1.59	3.91	.69
Marital status (nonmarried versus married)	−1.38	3.61	.70
Employment status (not working, but not due to health versus working)	3.50	3.62	.34
Employment status (unable to work due to health issues versus working)	−1.70	3.67	.65
Medical factors			
Diagnosis (CLL versus ALL)	6.51	3.63	.08
Diagnosis (NHL versus ALL)	−0.33	3.63	.93
No. of prior lines of therapy	−0.41	0.84	.63
CNS disease involvement (yes versus no)	−3.82	4.19	.37
CNS-directed chemotherapy before CAR T (yes versus no)	−3.73	3.17	.25
CRS (2–4 versus 0–1)	−3.59	2.94	.23
Neurotoxicity (2–4 versus 0–1)	−1.86	3.12	.55
Allogeneic HCT before CAR T (versus no allogeneic HCT at any time)	−4.12	3.60	.26
Allogeneic HCT after CAR T (versus no allogeneic HCT at any time)	−5.14	3.57	.16
Remission status (remission versus not in remission at time of questionnaire completion)	0.14	4.11	.97
Assessment year after CAR T cells	−2.65	1.28	.04
Psychiatric problems before CAR T (yes versus no)			
Depression <sup>†</sup>	−6.25	3.20	.06
Anxiety	−3.09	3.14	.33
Insomnia	−0.28	3.09	.93
Substance use disorder	6.21	5.76	.29
Multivariate analysis <sup>‡,§</sup>			
Age at time of CAR T therapy	0.27	0.12	.03
Assessment year after CAR T cells	−2.23	1.22	.08

\* Adjusted for depression before CAR T therapy.

† Not adjusted for depression before CAR T therapy.

‡ Multivariate analyses were performed on selected outcomes using stepwise selection, with a *P* value threshold of less than .10 for model entry and exit. All variables in the univariate analyses were included in the multivariable selection process.

§ Adjusted for depression prior to CAR-T therapy.

Adjusted of the multivariate analysis for allogeneic HCT before or after CAR-T cell therapy did not change the results.

Our findings demonstrate similar PROMIS global physical health among patients at 1 to 5 years after CAR T cell therapy (mean T score 48.8) and the general population. This is consistent with prior studies demonstrating similar PROMIS global physical health scores in survivors of hematologic cancers (mean T score 48.5) [44], older adults with cancer (mean T score 48) [45], and long-term survivors after allogeneic or autologous HCT (median T scores 50.8 and 47.7, respectively) [26]. Similarly, PROMIS global mental health in our cohort (mean T score 48.9) was similar to the general population or other cancer patient population. In comparison, mean PROMIS global mental health T scores of 51.7 and 51 were found in hematologic cancer survivors and in older adults with cancer, respectively [44,45], and Shaw et al. [26] found a median PROMIS global mental T score of 50.8 among long-term transplant survivors. Furthermore, allogeneic HCT before or after CAR T cell therapy did not seem to affect the PROMIS global mental score of patients in our cohort.

Older age was statistically significantly associated with better global mental health and less anxiety and depression, which is consistent with prior studies that demonstrated younger age as a risk factor for worse mental health in patients

with cancer [24,26,44,46]. In addition, we found that having more cognitive difficulties was associated with worse global mental and physical health, as well as more pain, fatigue, sleep disturbance, depression, and anxiety. This finding is consistent with Reid-Arndt et al. [47], who demonstrated an association between worse cognitive function and poorer quality of life in patients with breast cancer.

Although no inpatient longitudinal data are currently available in our cohort, our data suggest worse global mental health later after treatment. A potential explanation to this finding is that early after CAR T cell therapy, patients may be relieved to be alive given their previously refractory cancer. However, over time, survival may hold less psychological weight as patients adjust back to life and need to cope with ongoing symptoms and other psychosocial stressors. In the future, it will be important to examine longitudinal data for individual patients.

Of the patients in our cohort, 37.5% reported at least 1 cognitive difficulty. Similar cognitive difficulties (memory, attention, concentration) are known to arise after chemotherapy and HCT, with rates of impairment varying between 16% and 50% among cancer survivors assessed between 6 months and 10 years after treatment [47–50]. In an HCT survivor population 5 years after

**Table 4**  
Risk Factor Regression Analyses for Cognitive Difficulties (Any versus None)

Variable	Odds Ratio	95% Confidence Interval	P Value
Univariate analysis			
Demographics			
Age at time of CAR T therapy	0.97	0.92-1.03	.34
Sex (male versus female)	0.34	0.09-1.28	.11
Race (white versus other)	infinite	infinite	.03*
Marital status (nonmarried versus married)	2.62	0.58-12.76	.21
Employment status (not working, but not due to health versus working)	0.32	0.04-1.74	.21
Employment status (unable to work due to health issues versus working)	1.43	0.32-6.52	.64
Medical factors			
Diagnosis (CLL versus ALL)	0.44	0.08-2.25	.32
Diagnosis (NHL versus ALL)	0.90	0.18-4.52	.90
No. of prior lines of therapy	0.91	0.63-1.29	.60
CNS disease involvement (yes versus no)	4.18	0.71-33.66	.13
CNS-directed chemotherapy before CAR T (yes versus no)	2.25	0.59-8.86	.23
CRS (2-4 versus 0-1)	2.17	0.59-8.72	.25
Neurotoxicity (2-4 versus 0-1)	3.62	0.94-15.02	.07
Allogeneic HCT before CAR T (versus no allogeneic HCT at any time)	2.00	0.41-10.16	.39
Allogeneic HCT after CAR T (versus no allogeneic HCT at any time)	1.71	0.36-8.4	.50
Remission status (remission versus not in remission at time of questionnaire completion)	0.23	0.01-1.53	.19
Assessment year after CAR T cells	0.97	0.54-1.74	.91
Psychiatric problems before CAR T (yes versus no)			
Depression	6.00	1.45-28.93	.02
Anxiety	2.03	0.56-7.72	.29
Insomnia	1.71	0.47-6.42	.41
Multivariate analysis <sup>†</sup>			
Neurotoxicity (2-4 versus 0-1)	3.83	0.88-18.8	.08
Depression pre-CAR T	6.28	1.41-33.7	.02

\* Due to a 0 cell (0 nonwhite patients with cognitive difficulties), Fisher exact test was used to calculate P values.

<sup>†</sup> Multivariate analyses were performed on selected outcomes using stepwise selection, with a P value threshold of less than .10 for model entry and exit. All variables in the univariate analyses were included in the multivariable selection process.

Adjusted of the multivariate analysis for allogeneic HCT before or after CAR-T cell therapy did not change the results.

transplant, 41.5% had at least mild impairment on neuropsychologic function [49]. It is notable that in our cohort, age, number of prior therapies, allogeneic HCT before or after CAR T cell therapy, and presence or severity of CRS were not associated with self-reported cognitive difficulties. However, there was a trend toward association between early neurotoxicity and reported cognitive difficulties. Similarly, delirium immediately following hematopoietic stem cell transplant has been shown to be associated with subjective reports of worse memory and executive functioning 6 months and 1 year after HCT [51]. Larger studies of patients receiving CAR T cell therapy are necessary to determine if there is significant association between acute neurotoxicity after CAR T cell therapy and long-term cognitive impairment. Although acute neurotoxicity is a well-documented adverse event of CAR T cell therapy, only limited data are available regarding its risk factors and pathophysiology [15,52,53]. Better understanding of acute neurotoxicity after CAR T cell administration is needed to understand the potential association between acute neurotoxicity and long-term neurocognitive outcomes after CAR T cell therapy.

Our data demonstrate a potential association between race and patient-reported cognitive difficulties, as 45% of white patients reported at least 1 cognitive difficulty, whereas none of the nonwhite patients reported any cognitive difficulties. It could be that the difference in reported cognitive status is derived from cultural differences, but a larger cohort is needed to validate those findings. In addition, as there is some evidence that self-reported cognitive impairment may not correlate with objective cognitive function [54,55], it will be useful to include objective cognitive testing in future studies.

Correlation analysis of PROMIS outcomes (Figure 2) confirms strong associations between social function and physical and mental health, as well as a strong inverse association between social function and fatigue, pain, and sleep disturbance. In addition, the findings highlight the inverse association between fatigue and global mental and physical health. Fatigue is one of the most common and distressing symptoms for patients with cancer, and these correlations further argue for the importance of providing cancer survivors access to treatments for fatigue [56-58].

Although our results suggest overall no difference in mean mental health in patients after CAR T cell therapy compared with the mean of the general population, a subset of patients had clinically meaningful mental (30%) issues (PROMIS T score greater than half of the standard deviation) or cognitive (17.5%) impairment. Our regression analyses suggest that younger age, longer time since treatment, depression pre-CAR T, and acute neurotoxicity are potential risk factors for these negative outcomes. This demonstrates the need for longitudinal clinical monitoring of survivors' neuropsychiatric symptoms, particularly among younger patients, and connecting them with mental health and neurologic services as well as cognitive rehabilitation services [44,59]. Drawing from our multivariate analyses, future studies should examine whether preventing or treating depression and neurotoxicity during CAR T cell therapy can help prevent long-term neuropsychiatric problems.

Limitations of our study include sampling bias (including patients who survived at least 1 year after CAR T cell therapy), small sample size, lack of standardized neuropsychiatric and




Figure 2. Association between cognitive difficulties and PROMIS outcomes.




Figure 3. Correlation analysis of PROMIS scores.



cognitive assessments, lack of baseline PRO data at time of treatment, and variability in time points when data were collected post-treatment (between 1 and 5 years) with no inpatient longitudinal assessment after treatment. As pre-CAR T data were derived from medical records and post-CAR T data were derived from PROs, we cannot directly compare neuropsychiatric symptoms before and after treatment. Future studies comparing PROMIS measures before and after CAR T cell therapy will be necessary to understand better the direct impact of CAR T cell therapy on neuropsychiatric outcomes. In addition, it will be useful to collect longitudinal PRO data to understand the trajectory of neuropsychiatric outcomes over time. Our study did not include domains of spirituality and religiosity. As CAR T cell therapy is being given worldwide, future studies may include these domains to understand better how cultural, spiritual, and religious differences throughout the world potentially affect neuropsychiatric outcome after CAR T cell therapy.

In conclusion, despite acute neurotoxicity, our findings suggest overall good neuropsychiatric outcomes in long-term survivors after CAR T cell therapy. However, a subset of patients may experience psychiatric symptoms or cognitive impairment (which may be related to CAR T cell therapy or other treatments patients have been exposed to), and it is important to identify those patients to assist with intervention strategies.

#### ACKNOWLEDGMENTS

The authors thank the patients who participated in the clinical trial and answered the questionnaire, the members of the research and clinical staff at the FHCRC/Seattle Cancer Care Alliance, and referring physicians for their care of our patients after CAR T cell therapy.

**Financial disclosure:** This study was supported by the National Institutes of Health (NIH) National Cancer Institute (grants [R01 CA136551](#) and [P30 CA15704](#)); NIH National Institute of Diabetes and Digestive and Kidney Diseases (grant [P30 DK56465](#)); NIH National Heart, Lung, and Blood Institute funded National Gene Vector Biorepository at Indiana University (contract 75N92019D00018); Life Science Discovery Fund; Bezos Family; FHCRC Immunotherapy Integrated Research Center; and Juno Therapeutics/Celgene, Inc.

**Conflict of interest statement:** J.R., E.M., N.C., A.C., E.D.B., V.W., J.V., B.E.S., K.F., S.J.L., J.R.F., and M.B. declare no competing financial interests. C.J.T. receives research funding from Juno Therapeutics and Nektar Therapeutics; has served on the advisory board of Precision Biosciences, Eureka Therapeutics, Caribou Biosciences, T-CURX, Nektar Therapeutics, Allogene, Kite/Gilead, Novartis, and Humanigen; and has stock/options in Precision Biosciences, Eureka Therapeutics, and Caribou Biosciences. D.G.M. has received research funding from Kite Pharma (a Gilead Company), Juno Therapeutics (a Celgene/Bristol-Myers Squibb Company), and Celgene and has served on advisory boards for Kite Pharma, Gilead, Genentech, Novartis, and Eureka Therapeutics.

#### SUPPLEMENTARY MATERIALS

Supplementary data related to this article can be found online at doi:[10.1016/j.bbmt.2019.09.037](https://doi.org/10.1016/j.bbmt.2019.09.037).

#### REFERENCES

- Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. *N Engl J Med*. 2018;378(5):439–448.
- Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. *N Engl J Med*. 2017;377(26):2531–2544.
- Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. *N Engl J Med*. 2019;380(1):45–56.
- Kansagra AJ, Frey NV, Bar M, et al. Clinical utilization of chimeric antigen receptor T cells in B cell acute lymphoblastic leukemia: an expert opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2019;25(3):e76–e85.
- Jain T, Bar M, Kansagra AJ, et al. Utilization of chimeric antigen receptor (CAR) T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy. *Biol Blood Marrow Transplant*. 2019;25(12):2305–2321.
- Byrne M, Oluwole OO, Savani B, et al. Understanding and managing large B cell lymphoma relapses after chimeric antigen receptor T cell therapy. *Biol Blood Marrow Transplant*. 2019;25(11):e344–e351.
- Hay KA, Gauthier J, Hirayama AV, et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. *Blood*. 2019;133(15):1652–1663.
- Hirayama AV, Gauthier J, Hay KA, et al. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. *Blood*. 2019;133(17):1876–1887.
- Turtle CJ, Hay KA, Hanafi LA, et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib. *J Clin Oncol*. 2017;35(26):3010–3020.
- Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. *Blood*. 2014;124(2):188–195.
- Hay KA, Hanafi LA, Li D, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. *Blood*. 2017;130(21):2295–2306.
- Frey N, Porter D. Cytokine release syndrome with chimeric antigen receptor T cell therapy. *Biol Blood Marrow Transplant*. 2019;25(4):e123–e127.
- Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. *Biol Blood Marrow Transplant*. 2019;25(4):625–638.
- Wang J, Hu Y, Yang S, et al. Role of fluorodeoxyglucose positron emission tomography/computed tomography in predicting adverse effects of chimeric antigen receptor T cell therapy in patients with non-Hodgkin lymphoma. *Biol Blood Marrow Transplant*. 2019;25(6):1092–1098.
- Gust J, Hay KA, Hanafi LA, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. *Cancer Discov*. 2017;7(12):1404–1419.
- Santomasso BD, Park JH, Salloum D, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. *Cancer Discov*. 2018;8(8):958–971.
- Hay KA. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy. *Br J Haematol*. 2018;183(3):364–374.
- Cordeiro A, Bezerra ED, Hirayama AV, et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells. *Biol Blood Marrow Transplant*. 2019;26(1):26–33.
- Inamoto Y, Lee SJ. Late effects of blood and marrow transplantation. *Hematologica*. 2017;102(4):614–625.
- Basch E, Jia X, Heller G, et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. *J Natl Cancer Inst*. 2009;101(23):1624–1632.
- Di Maio M, Basch E, Bryce J, Perrone F. Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. *Nat Rev Clin Oncol*. 2016;13(5):319–325.
- Basch E, Deal AM, Dueck AC, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. *JAMA*. 2017;318(2):197–198.
- Yost KJ, Eton DT, Garcia SF, Cella D. Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients. *J Clin Epidemiol*. 2011;64(5):507–516.
- Jensen RE, Potosky AL, Moinpour CM, et al. United States population-based estimates of Patient-Reported Outcomes Measurement Information System symptom and functional status reference values for individuals with cancer. *J Clin Oncol*. 2017;35(17):1913–1920.
- Cella D, Choi S, Garcia S, et al. Setting standards for severity of common symptoms in oncology using the PROMIS item banks and expert judgment. *Qual Life Res*. 2014;23(10):2651–2661.
- Shaw BE, Syrjala KL, Onstad LE, et al. PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors. *Cancer*. 2018;124(4):841–849.
- Pidala J, Kurland B, Chai X, et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. *Blood*. 2011;117(17):4651–4657.
- Malhotra J, Jabbar SK. Patient-related outcomes with the use of checkpoint inhibitors for the treatment of metastatic non-small cell lung cancer. *Transl Lung Cancer Res*. 2018;7(Suppl 2):S138–S141.

29. Hall ET, Singhal S, Dickerson J, et al. Patient-reported outcomes for cancer patients receiving checkpoint inhibitors: opportunities for palliative care: a systematic review. *J Pain Symptom Manage.* 2019;58(1):137–156.e1.
30. Harrington KJ, Ferris RL, Blumenschein Jr G, et al. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. *Lancet Oncol.* 2017;18(8):1104–1115.
31. Reck M, Brahmer J, Bennett B, et al. Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057. *Eur J Cancer.* 2018;102:23–30.
32. Reck M, Taylor F, Penrod JR, et al. Impact of nivolumab versus docetaxel on health-related quality of life and symptoms in patients with advanced squamous non-small cell lung cancer: results from the CheckMate 017 Study. *J Thorac Oncol.* 2018;13(2):194–204.
33. Tykodi SS, Schadendorf D, Cella D, et al. Patient-reported outcomes with nivolumab in advanced solid cancers. *Cancer Treat Rev.* 2018;70:75–87.
34. Chakraborty R, Sidana S, Shah GL, Scordo M, Hamilton BK, Majhail NS. Patient-reported outcomes with chimeric antigen receptor T cell therapy: challenges and opportunities. *Biol Blood Marrow Transplant.* 2019;25(5):e155–e162.
35. Cella D, Riley W, Stone A, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008. *J Clin Epidemiol.* 2010;63(11):1179–1194.
36. Liu H, Cella D, Gershon R, et al. Representativeness of the Patient-Reported Outcomes Measurement Information System Internet panel. *J Clin Epidemiol.* 2010;63(11):1169–1178.
37. Rothrock NE, Hays RD, Spritzer K, Yount SE, Riley W, Cella D. Relative to the general US population, chronic diseases are associated with poorer health-related quality of life as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS). *J Clin Epidemiol.* 2010;63(11):1195–1204.
38. Thekkumpurath P, Walker J, Butcher I, et al. Screening for major depression in cancer outpatients: the diagnostic accuracy of the 9-item patient health questionnaire. *Cancer.* 2011;117(1):218–227.
39. Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. *Med Care.* 2003;41(11):1284–1292.
40. Esser P, Hartung TJ, Friedrich M, et al. The Generalized Anxiety Disorder Screener (GAD-7) and the anxiety module of the Hospital and Depression Scale (HADS-A) as screening tools for generalized anxiety disorder among cancer patients. *Psychooncology.* 2018;27(6):1509–1516.
41. Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. *Gen Hosp Psychiatry.* 2016;39:24–31.
42. Lee SJ, Onstad L, Chow EJ, et al. Patient-reported outcomes and health status associated with chronic graft-versus-host disease. *Haematologica.* 2018;103(9):1535–1541.
43. Khera N, Hamilton BK, Pidala JA, et al. Employment, insurance, and financial experiences of patients with chronic graft-versus-host disease in North America. *Biol Blood Marrow Transplant.* 2019;25(3):599–605.
44. Weaver KE, Forsythe LP, Reeve BB, et al. Mental and physical health-related quality of life among U.S. cancer survivors: population estimates from the 2010 National Health Interview Survey. *Cancer Epidemiol Biomarkers Prev.* 2012;21(11):2108–2117.
45. Pergolotti M, Deal AM, Williams GR, et al. Activities, function, and health-related quality of life (HRQOL) of older adults with cancer. *J Geriatr Oncol.* 2017;8(4):249–254.
46. Sun CL, Francisco L, Baker KS, Weisdorf DJ, Forman SJ, Bhatia S. Adverse psychological outcomes in long-term survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study (BMTSS). *Blood.* 2011;118(17):4723–4731.
47. Reid-Armdt SA, Hsieh C, Perry MC. Neuropsychological functioning and quality of life during the first year after completing chemotherapy for breast cancer. *Psychooncology.* 2010;19(5):535–544.
48. Ono M, Ogilvie JM, Wilson JS, et al. A meta-analysis of cognitive impairment and decline associated with adjuvant chemotherapy in women with breast cancer. *Front Oncol.* 2015;5:59.
49. Syrjala KL, Artherholt SB, Kurland BF, et al. Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors compared with matched controls at 5 years. *J Clin Oncol.* 2011;29(17):2397–2404.
50. Vitali M, Ripamonti CI, Roila F, et al. Cognitive impairment and chemotherapy: a brief overview. *Crit Rev Oncol Hematol.* 2017;118:7–14.
51. Basinski JR, Alfano CM, Katon WJ, Syrjala KL, Fann JR. Impact of delirium on distress, health-related quality of life, and cognition 6 months and 1 year after hematopoietic cell transplant. *Biol Blood Marrow Transplant.* 2010;16(6):824–831.
52. Gust J, Taraseviciute A, Turtle CJ. Neurotoxicity associated with CD19-targeted CAR-T cell therapies. *CNS Drugs.* 2018;32(12):1091–1101.
53. Hunter BD, Jacobson CA. CAR T-cell associated neurotoxicity: mechanisms, clinicopathologic correlates, and future directions [e-pub ahead of print]. *J Natl Cancer Inst.*
54. Biglia N, Bounous VE, Malabaila A, et al. Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study. *Eur J Cancer Care (Engl).* 2012;21(4):485–492.
55. Gehring K, Taphoorn MJ, Sitskoorn MM, Aaronson NK. Predictors of subjective versus objective cognitive functioning in patients with stable grades II and III glioma. *Neurooncol Pract.* 2015;2(1):20–31.
56. Breitbart WS, Alici Y. Psycho-oncology. *Harv Rev Psychiatry.* 2009;17(6):361–376.
57. Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR. Cancer-related fatigue: the scale of the problem. *Oncologist.* 2007;12((Suppl 1)):4–10.
58. Hjermstad MJ, Knobel H, Brinch L, et al. A prospective study of health-related quality of life, fatigue, anxiety and depression 3–5 years after stem cell transplantation. *Bone Marrow Transplant.* 2004;34(3):257–266.
59. Wefel JS, Kesler SR, Noll KR, Schagen SB. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. *CA Cancer J Clin.* 2015;65(2):123–138.